Efficacy of Alpha-Blocker Add-on Therapy to Tadarafil Treated Men with Lower Urinary Tract Sympton

Efficacy of Alpha-Blocker Add-on Therapy to Tadarafil Treated Men with Lower Urinary Tract Sympton - Efficay of Alpha-Blocker Add-on Therapy to Tadarafil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015311

Enrollment

Registered

2014-10-01

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hypertrophy

Interventions

The patients were randomly divided into two groups: alpha1A blocker add-on group or alpha1D blocker add-on group.Patients in each group were administered drugs for 6 weeks. Following 2-week drug withd

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Prostate volume > 20cc 2. LUTS sympton (IPPS>8 and Qmax 5-15ml/sec) after taking tadarafil for 3 or more months.

Exclusion criteria

Exclusion criteria: 1. Prostate cancer 2. Episode of urinary retention within 6 months 3. Residual urine volume >150ml 4. Urinary tract infection, neurogenic bladder

Design outcomes

Primary

Measure	Time frame
OABSS, IPSS and urodynamic parameter such as Qmax and residual volue of urine.	—

Countries

Japan

Contacts

Public ContactToshiaki Shinojima

Keio University School of Medicine Department of Urology

t-shinoj@cd5.so-net.ne.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026